NCT01612988终止2 期
Phase II Salvage Treatment With Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in Relapsed B-cell Chronic Lymphocytic Leukemia (B-CLL)
French Innovative Leukemia Organisation1 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- Efficacy: Response rate according to IWCLL 2008 guidelines
研究概览
简要总结
ICLL01 The BOMP trial: Phase II study of salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL).
A study of the GOELAMS / GCFLLC-MW intergroup
详细描述
Available datas suggest that a combination of bendamustine, ofatumumab and high dose steroids (the BOMP regimen) appears meaningful and likely to induce a high response rate in patients with relapsed CLL, including those who have relapsed after modern 1st line immuno-chemotherapy combinations and those who are fludarabine-refractory. The BOMP trial will address the complete response rate as its main objective. The results of bendamustine and rituximab CLL2M trial will serve of a comparator for the BOMP trial. Among secondary objectives, an extensive study of the p53 pathway (deletion 17p, TP53 mutational status and p53 function) will be performed and its impact on response and survival will be analyzed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years and < 80 years
- •Diagnosis of CLL according IWCLL 2008 criteria and fulfilling a Matutes- Moreau score ≥ 4
- •Relapsed or refractory CLL stage A, B or C with active disease requiring therapy according to IWCLL 2008 criteria
- •Relapse or refractory after 1 to 3 previous lines including at least one line with fludarabine
- •ECOG Performance status and general condition.
- •ECOG Performance status ≤ 2
- •Fit Patients : CIRS (Cumulative Illness Rating Scale) less or equal 6
- •Life expectancy of more than 3 months
- •Note : Patients fulfilling the above inclusion criteria and presenting with the following features can also be included:
- •patients with any rate of 17p deletion by FISH
- •patients candidate for an allogeneic transplantation, provided these patients will be planned to receive the full BOMP treatment program and will have the final restaging assessment
- •patients with fludarabine refractory disease
- •patients with a prior diagnostic of CLL, at time of previous line(s) of treatment but who relapse without hyperlymphocytosis (lymphocytes < 5000/mm3) (lymphocytic lymphoma)
- •prior monoclonal antibody (alemtuzumab or rituximab) exposure provided a washout period of 3 months before the start of the BOMP treatment.
排除标准
- •Untreated CLL
- •ECOG Performance Status > 2
- •Serious accompanying disorder or impaired organ function as indicated by:
- •Abnormal renal function with creatinine clearance < 40 ml/min calculated according to the formula of Cockcroft and Gault
- •Absolute neutrophils <1,000/mm3, platelets < 75000/mm3 (unless due to malignant B Cell involvement of the bone marrow and/or spleen enlargement)
- •Liver tests : total bilirubin >1.5 times UNL (unless due to CLL involvement of liver or a known history of Gilbert's disease), transaminases (ALAT, ASAT) and/or alkaline phosphatases >2.5 times UNL (unless due to CLL involvement of liver)
- •Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to study enrollment, congestive heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities.
- •Severe chronic obstructive pulmonary disease with hypoxemia or pulmonary diffusion capacity < 40 %
- •Uncontrolled diabetes mellitus,
- •Uncontrolled hypertension
- •History of significant cerebrovascular disease in the past 6 months or ongoing event with active symptoms or sequelae
- •Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient.
- •CIRS (Cumulative Illness Rating Scale) > 6
- •Clinically significant auto-immune anemia [i.e. any drop in hemogolobin level related to an hemolytic autoimmune process attested by the following markers : elevated indirect bilirubin, elevated LDH, low haptoglobin levels, high reticulocytes count along with a positive direct anti-erythrocyte test (Coombs direct test)]
- •Transformation to an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin's lymphoma, or prolymphocytic leukaemia)
- •Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months prior to start of therapy.
- •Prior autologous transplantation or allogeneic transplantation
- •Prior treatment with bendamustine and/or ofatumumab
- •Active second malignancy currently requiring treatment (except basal cell carcinoma, in situ cervix carcinoma and incidental prostate carcinoma). Subjects who have been free of malignancy for at least 5 years are eligible.
- •Known HIV-positivity
- •Positive serology for hepatitis B (HB) (except post vaccinale pattern) and/or for hepatitis C. Positive serology for HB is defined as a positive test for HBs antigen or for anti-HBc antibodies (regardless of HBsAb status).
- •Current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator assessment)
- •Simultaneous participation in another study protocol
- •Known hypersensitivity to the medications to be used specially to humanized monoclonal antibodies or any of the study drugs
- •Chronic or current bacterial, viral or fungal infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis
- •Any coexisting medical or psychological condition that would preclude participation in the required study procedures
- •Patient with mental deficiency preventing proper understanding of the requirements of treatment.
- •Pregnant or breastfeeding women.
- •Person major under law-control
- •Lactating women
- •Fertile male and female patients who cannot or do not wish to use an effective method of contraception, during and for 12 months after the final treatment used for the purposes of the study.
研究组 & 干预措施
Chemotherapy BOMP
Experimental
Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
干预措施: BOMP (Drug)
结局指标
主要结局
Efficacy: Response rate according to IWCLL 2008 guidelines
时间窗: 9 months
Complete response rate (CR) at 6 cycles of BOMP according to IWCLL 2008 criteria Hallek 2008
次要结局
- Tolerance and safety(57 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular LymphomaGrade 3a Follicular LymphomaNCT01286272National Cancer Institute (NCI)135
终止
2 期
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT01010568Georgetown University10
终止
2 期
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell LymphomaDiffuse Large B-Cell LymphomaNCT02420210University of Chicago2
招募中
2 期
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaPlasma Cell MyelomaNCT05208307Emory University34
进行中（未招募）
2 期
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell LymphomaCCND1 Positivet(11;14) PositiveMantle Cell LymphomaNCT03872180Emory University23